Cary Street Partners Financial LLC Makes New Investment in Humana Inc. (NYSE:HUM)

Cary Street Partners Financial LLC bought a new stake in Humana Inc. (NYSE:HUM - Free Report) in the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor bought 2,736 shares of the insurance provider's stock, valued at approximately $694,000.

Other institutional investors and hedge funds have also recently bought and sold shares of the company. FPC Investment Advisory Inc. bought a new position in shares of Humana during the 4th quarter valued at about $27,000. Centricity Wealth Management LLC acquired a new position in shares of Humana in the fourth quarter worth about $30,000. LFA Lugano Financial Advisors SA boosted its holdings in shares of Humana by 56.3% in the fourth quarter. LFA Lugano Financial Advisors SA now owns 125 shares of the insurance provider's stock worth $32,000 after buying an additional 45 shares during the period. OFI Invest Asset Management acquired a new position in shares of Humana in the fourth quarter worth about $33,000. Finally, Transce3nd LLC acquired a new position in shares of Humana in the fourth quarter worth about $38,000. Institutional investors own 92.38% of the company's stock.

Humana Price Performance

NYSE:HUM traded up $1.29 during trading hours on Wednesday, hitting $230.18. 877,503 shares of the stock were exchanged, compared to its average volume of 1,749,470. The company has a current ratio of 1.76, a quick ratio of 1.76 and a debt-to-equity ratio of 0.68. The firm's fifty day moving average price is $264.29 and its 200 day moving average price is $270.12. The company has a market cap of $27.78 billion, a P/E ratio of 23.13, a P/E/G ratio of 2.05 and a beta of 0.49. Humana Inc. has a 52-week low of $213.31 and a 52-week high of $406.46.

Humana (NYSE:HUM - Get Free Report) last posted its earnings results on Wednesday, April 30th. The insurance provider reported $11.58 earnings per share for the quarter, topping the consensus estimate of $10.07 by $1.51. Humana had a return on equity of 11.70% and a net margin of 1.02%. The firm had revenue of $32.11 billion during the quarter, compared to analysts' expectations of $32 billion. During the same quarter in the previous year, the business earned $7.23 earnings per share. The firm's revenue was up 8.4% compared to the same quarter last year. As a group, equities research analysts anticipate that Humana Inc. will post 16.47 EPS for the current fiscal year.

Humana Dividend Announcement

The firm also recently announced a quarterly dividend, which will be paid on Friday, July 25th. Stockholders of record on Friday, June 27th will be given a $0.885 dividend. The ex-dividend date is Friday, June 27th. This represents a $3.54 annualized dividend and a dividend yield of 1.54%. Humana's dividend payout ratio (DPR) is presently 25.04%.

Wall Street Analysts Forecast Growth

Several analysts recently commented on HUM shares. Cantor Fitzgerald restated a "neutral" rating and set a $290.00 price target on shares of Humana in a report on Thursday, May 1st. Raymond James upgraded shares of Humana from a "market perform" rating to an "outperform" rating and set a $315.00 price target for the company in a report on Thursday, May 1st. Guggenheim assumed coverage on shares of Humana in a research note on Wednesday, April 9th. They issued a "buy" rating and a $326.00 target price for the company. Royal Bank of Canada reiterated an "outperform" rating and issued a $283.00 target price on shares of Humana in a research note on Wednesday, February 12th. Finally, Morgan Stanley dropped their price target on shares of Humana from $301.00 to $285.00 and set an "equal weight" rating on the stock in a research report on Wednesday, February 12th. Seventeen analysts have rated the stock with a hold rating and eight have issued a buy rating to the company. Based on data from MarketBeat, Humana has a consensus rating of "Hold" and an average price target of $286.81.

About Humana

Humana Inc, together with its subsidiaries, provides medical and specialty insurance products in the United States. It operates through two segments, Insurance and CenterWell. The company offers medical and supplemental benefit plans to individuals. It has a contract with Centers for Medicare and Medicaid Services to administer the Limited Income Newly Eligible Transition prescription drug plan program; and contracts with various states to provide Medicaid, dual eligible, and long-term support services benefits.